| Market Cap | ₹211.26 CrPharmaceuticals |
|---|---|
| P/E TTM | 21.85Sector P/E 45.87 |
| 1Yr Price Change | 234.89%LTP 190.05 |
| Promoter Holding | 73.52%No pledge |
| Metric | H1-27 | H2-26 | H1-26 |
|---|---|---|---|
| Revenue from Operations | 55.0 | 45.9 | 43.7 |
| Other Income | 0.1 | 0.1 | 0.1 |
| Total Income | 55.2 | 46.0 | 43.8 |
| Profit Before Tax | 10.8 | 6.7 | 6.4 |
| Net Profit | 8.2 | 4.9 | 4.8 |
| Operating Margin | 19.6% | 14.6% | 14.6% |
| Net Profit QoQ | +67.3% | ||
| Net Profit YoY | +70.8% | ||
| Adj. Profit QoQ | +62.1% | ||
| Adj. Profit YoY | +69.8% | ||
Key highlights
- Revenue from operations grew to ₹55.0 crore in H1-27, up from ₹43.7 crore in the previous year's first half
- Net profit witnessed a sharp 70.8% year-on-year rise to ₹8.2 crore from ₹4.8 crore
- Operating margins expanded to 19.6%, a 500 basis point improvement over the 14.6% recorded in H1-26
- Profit before tax for the period stood at ₹10.8 crore, reflecting a 68.7% growth compared to H1-26
- The company reported a basic and diluted EPS of ₹7.38 for the half-year ended September 30, 2026
Manufacturing Scale Drives Margin Expansion
Accretion Pharmaceuticals demonstrated significant operational efficiency during the first half of the fiscal year, with revenue from operations reaching ₹55.0 crore. This growth follows the company's strategic 40% capacity expansion implemented in May 2026, which has enhanced its capability in the formulation and CDMO segments. The operating margin improved to 19.6%, up from 14.6% in the corresponding period of the previous year.
This expansion in profitability comes as the company leverages its fully utilized IPO proceeds, which were deployed for capacity augmentation and working capital requirements as of March 2026.
Operational Milestones and Business Focus
- Company listed on the NSE Emerge platform on May 21, 2025, following a ₹29.75 crore IPO
- Funds raised through the initial public offering were fully utilized as of March 31, 2026
- Business operations remain concentrated in manufacturing and trading of pharmaceutical products and drugs
- Secured Current Good Manufacturing Practice approval from PMRA Malawi in September 2025
- Management maintains a target of 20%+ top-line growth following recent capacity expansions
Sequential Growth and Market Performance
On a half-year-over-half-year basis, the company saw a 67.3% increase in net profit, rising from ₹4.9 crore in H2-FY26 to ₹8.2 crore in H1-FY27. Revenue also trended upward from ₹45.9 crore in the preceding half-year. The stock has reflected this operational momentum, recording a 234.89% price increase over the last year.
Despite the recent monthly correction of 9.91%, the company's valuation remains at a P/E of 21.85, which is significantly lower than the industry average of 40.83. Institutional holding currently stands at 3.82%, showing a marginal quarterly increase of 1.06%.
Regulatory Compliance and Board Approval
The Board of Directors of the Company at its meeting held today i.e. 31st October, 2026 has, inter-alia considered and approved Unaudited Financial Results for the half-year ended 30th September, 2026 along with Limited Review Reports of the Statutory Auditors thereon.
What to watch next
- Full year FY27 audited results expected by May 2027
- Execution progress of the 40% capacity expansion announced in May 2026
- Potential renewal or expansion of regulatory approvals following the Malawi PMRA certification
“The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kind of Drugs, Pharmaceuticals products and related products thereto.”
| Share price | ₹190.05 |
|---|---|
| Market capitalisation | ₹211.26 Cr |
| Revenue (annual) | ₹89.63 Cr |
| Net profit (annual) | ₹9.67 Cr |
| P/E (TTM) | 21.85×Sector 45.87× |
| Promoter holding | 73.52%0.00% QoQ |
| FII holding | 0.17%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Half-year financial results filing by Accretion Pharmaceuticals Limited for the period ended September 30, 2026. Market figures from a third-party data provider.
